Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17033153 | 0.87 | SMN1; SMN2 (0.56) | KDM4ESMN1; SMN2MEN1CYP3A4TSHR | |
| SCHEMBL20147364 | 0.86 | MEN1 (0.49) | SMN1; SMN2HRH3MEN1TSHRCYP2C19 | |
| SCHEMBL20147371 | 0.86 | SIGMAR1 (0.47) | SMN1; SMN2HRH3MEN1CYP3A4CYP2C19 | |
| SCHEMBL20147475 | 0.77 | CCR1 (0.34) | HRH3SIGMAR1 | |
| SCHEMBL20147467 | 0.76 | TP53 (0.38) | SMN1; SMN2CYP3A4CYP2C19SIGMAR1ALDH1A1 | |
| SCHEMBL20147307 | 0.75 | SIGMAR1 (0.32) | KDM4EHRH3SIGMAR1ALDH1A1 | |
| SCHEMBL20147471 | 0.74 | SIGMAR1 (0.37) | HRH3MEN1CYP3A4CYP2C19KMT2A | |
| SCHEMBL20147372 | 0.74 | HRH3 (0.34) | HRH3SIGMAR1 | |
| SCHEMBL20069014 | 0.73 | RET (0.36) | HRH3ALDH1A1 | |
| SCHEMBL20147519 | 0.73 | RET (0.40) | KDM4ESMN1; SMN2HRH3TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | KDM4E 547/4885SMN1; SMN2 646/4885HRH3 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.